Optimapharm has announced the expansion of its office network to New York, USA, and Budapest, Hungary. In addition, Optimapharm has appointed Roy Ovel as chief commercial officer and Charles Denis Maher as vice president Business Development (Americas).

Optimapharm is a European CRO with the leading position in Central and Southeast Europe and access to a market of over 300 million people.  At the begining of the year, Optimapharm acquired the leading Czech CRO company MKS Research. Today, Optimapharm is operating from 12 offices, including offices in 11 countries across Europe, through which it is covering activities in 18 European countries.

“We have already realized a number of projects in the US; however, by opening our office and strengthening our team, we wish to significantly strengthen our business development activities in the world’s biggest CRO market, to provide US clients with the advantages of conducting trials in Europe. Our continued focus on quality and expedited patient recruitment and retention has led to a 95-percent repeat business rate. This, combined with our strong track record and financial position, has allowed us to continue our growth in both Europe and the US. Roy and Charles joining the company will significantly strengthen our business development activities as they have experience of working globally with virtual and large pharmaceutical companies across the drug development continuum,” said Gordana Greguric Cicak, chief executive officer at Optimapharm. 

Roy has over 35 years of experience in the CRO industry during which, he has held numerous senior leadership positions at local CROs as well as larger multinational CROs (ICON & Worldwide Clinical Trials). 

Charles Denis Maher joins Optimapharm from the global CRO Sundia Meditech Company NY, headquartered in Shanghai, where he worked as Executive Director of Business Development USA. Maher has 25 years of managerial experience in CROs specialized in providing full-service solutions for full product development phases I through IV.